Avadel Pharmaceuticals (AVDL) announced that, in relation to the previously announced offer for the company by Alkermes (ALKS), pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the company, the resolutions required to approve the scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 were passed by the requisite majorities at the scheme meeting of shareholders and the related extraordinary general meeting of shareholders held earlier.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Completes Enrollment in Phase 3 LUMRYZ Trial
- Avadel Pharmaceuticals completes enrollment in Phase 3 REVITALYZ trial
- Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry
- Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market Uncertainties
- Jefferies expects Avadel-Alkermes deal to close